NAD+ Injection: What the Human Evidence Actually Covers

NAD+ injections are the middle option between an IV drip in a clinic and a nasal spray at home. They are given subcutaneously, they take minutes rather than hours, and they are the format most people end up on when they want NAD+ without an appointment.

What follows is what is documented about injected NAD+, what is not, and where the regulatory position sits. The short version: the human evidence for injected NAD+ specifically is thinner than the market implies, and most of what gets cited in support of it comes from studies of a different molecule taken by a different route.

What NAD+ is

Nicotinamide adenine dinucleotide is a coenzyme present in every cell. It is a required cofactor in the reactions cells use to produce ATP, it participates in DNA repair through the PARP enzymes, and it is involved in sirtuin signalling. Tissue concentrations decline with age in several animal models and in some human tissue studies.

That decline is the reasoning behind the entire NAD+ market. The reasoning is sound as far as it goes. Whether raising NAD+ from an external source produces meaningful clinical benefit in healthy adults is a separate question the literature has not settled.

The evidence problem, stated plainly

There is a distinction that most pages on this topic collapse, and it matters:

• Oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have multiple placebo-controlled human trials. They consistently raise blood NAD+ metabolite levels. Downstream clinical outcomes have been inconsistent, with generally small or absent effects in healthy adults.
• NAD+ itself, injected, has very limited published human data.

These are different molecules taken by different routes. A trial showing that oral NR raises NAD+ metabolites is not evidence for what a subcutaneous NAD+ injection does. When a page cites the Martens 2018 nicotinamide riboside trial in support of an injection product, it is borrowing evidence that does not transfer.

Injection compared with the other routes

	Subcutaneous injection	IV infusion	Nasal spray
Published human absorption data	Limited	Limited	None
Where	At home	Clinic or infusion centre	At home
Session length	Minutes	One to four hours	Seconds
Needle	Small gauge	Cannula	None
Commonly reported effects	Injection site reactions	Flushing, nausea, chest tightness during infusion	Nasal irritation
Available through PrescribedRX	Yes	No	Yes

No published human study has compared absorption or outcomes across these routes, so this page does not rank them. The differences that can be documented are practical ones. Anyone presenting a bioavailability percentage by route for NAD+ is presenting a figure that does not come from a human study.

Where the regulatory position stands

• There is no FDA approved NAD+ drug product by any route. Compounded NAD+ is an unapproved drug.
• NAD+ appears in Category 1 of FDA’s 503A bulk drug substances evaluation, list updated 14 May 2026, and on the 503B nominations list. Category 1 is a nomination and an interim enforcement discretion posture while FDA completes its evaluation. It is not an approval and not an endorsement, and the phrase “FDA Category 1 approved” describes something that does not exist.
• In a warning letter to GenoGenix LLC dated 20 January 2026, FDA stated that the facility “compounded drug products using bulk drug substances that are not eligible for the use in compounding under section 503B, including 5-amino-1-methylquinolinium iodide (5-Amino-1MQ) and nicotinamide adenine dinucleotide (NAD+)” and that products compounded with those substances “are not eligible for the exemptions provided by section 503B.” That letter concerned a 503B outsourcing facility. Section 503A, compounding against an individual prescription, is a separate pathway with separate eligibility rules.
• Olympia Pharmacy issued a nationwide recall of compounded sterile preparations including NAD and sermorelin on 10 March 2022 for out-of-specification product. That was a manufacturing quality failure rather than a finding about the substance.

The pathway question is worth asking your provider directly: which compounding pathway is the NAD+ you are being prescribed made under, and which pharmacy is filling it. A provider who can answer that is worth more than one who cannot.

What injections involve in practice

Subcutaneous injection means into the fat layer beneath the skin rather than into muscle, using a short, small-gauge needle. It is the same technique used for many self-administered medications.

Technique, site rotation, storage and disposal should be demonstrated by the prescriber or pharmacist rather than learned from an article. Reported effects centre on injection site reactions: redness, tenderness or swelling where the injection was given. Some people report flushing or a warm sensation.

Because there is no approved label, there is no standardised adverse event document of the kind an approved drug carries. That is a limitation of the evidence, not a demonstration of safety.

What the published human research on NAD injections actually is

This is the section most pages selling NAD do not write, so it is worth being specific rather than saying “research is ongoing”.

There are no published randomised controlled trials of injected or intravenous NAD+ in humans. Not few. None that we could locate in the peer reviewed literature. The entire published human record for the parenteral route is three items:

• An uncontrolled pilot, 2019. Eleven men, eight of whom received a single six hour infusion. It measured NAD+ and its metabolites in plasma and urine. Not randomised, not blinded. Funded by a company selling NAD therapy, with a co-author who directs a clinic providing it.
• A retrospective chart review, 2026. Fourteen people at a commercial wellness clinic, comparing NAD+ against a precursor. All seven authors were employed by that clinic and the study was funded by it.
• An unpublished preprint. Randomised, but not peer reviewed, and produced by a company that sells the competing precursor product.

That is the literature. Every one of the three has a commercial party attached to it, and there is no independently funded human study of intravenous NAD+ at all.

The FDA commissioned its own review of NAD in 2021 through a university regulatory science centre. Its systematic search across six decades identified five human studies in total, with sample sizes between one and 104, and recorded that the experts it consulted “remarked that there was limited clinical evidence supporting the use of NAD.”

The question nobody has answered: does it reach your cells?

The premise of NAD therapy is that infusing NAD+ raises the NAD+ inside your cells, where it does its work. That premise has never been tested in a human being.

The 2019 pilot, which is the study the entire field leans on, measured plasma and urine only. Its authors list the inability to measure NAD+ inside red blood cells among their own limitations. Nobody has measured the intracellular compartment after an infusion.

What the pilot did find is interesting and rarely quoted: despite continuous infusion, plasma NAD+ did not change at all for the first two hours. The infused NAD+ was being removed from circulation rapidly and completely. The authors are careful about why, and note it is consistent with either cellular uptake or with the molecule being broken down outside the cell by enzymes.

That second possibility matters. NAD+ is a large, electrically charged molecule. The straightforward biochemical expectation is that it is broken down outside the cell into smaller pieces, which are then transported in and reassembled. If that is what happens, intravenous NAD+ is an expensive and uncomfortable way to deliver a precursor rather than direct repletion. The human data does not distinguish between the two.

So the honest statement is: infusion clearly raises NAD+ in your blood. Whether it raises NAD+ in your cells is unknown, and anybody stating it as established is going beyond what has been measured.

What people actually report during an infusion

The 2026 clinic review is small, but it is the most candid tolerability data available, and it is not flattering.

Every NAD+ recipient reported moderate to severe symptoms during infusion: abdominal cramping, diarrhea, nausea, vomiting and chest pressure. Recipients of the comparison precursor reported only minor tingling.

Mean infusion time was 97 minutes for NAD+ against 37 minutes for the comparator. That long, slow drip is not a pharmacological requirement. It is a symptom avoidance measure. The infusion is slow because going faster is unpleasant.

No clinically significant changes to liver, kidney or inflammatory markers were seen at 30 days in that group, and no serious organ toxicity has been reported in any of the three studies. But those studies are tiny and short, so absence of a signal is weak evidence rather than reassurance.

Claims this page does not make

PrescribedRX dispenses NAD+ preparations, so it is worth being explicit about which common claims are deliberately absent:

• No bioavailability percentage for injected NAD+, because no published human pharmacokinetic study supports one.
• No ranking of injection against IV or nasal, because no comparative human study exists.
• No results timeline. No controlled trial establishes one.
• No use of oral NR or NMN trial results as evidence for injected NAD+.
• No description of NAD+ as FDA approved, FDA cleared or “Category 1 approved.”

Information a clinician will want

Because controlled human data is limited for every route, a prescriber will generally want a full history. Points that commonly matter include pregnancy or breastfeeding, a current or previous cancer diagnosis, significant kidney or liver impairment, and any medication with a narrow therapeutic window. NAD+ has not been studied in people with active cancer, which is a gap in the evidence rather than a finding in either direction.

Frequently asked

Is NAD+ injection FDA approved?

No. There is no FDA approved NAD+ drug product by any route.

Is injection better than IV?

No published human study has compared them, so the comparison cannot be made from evidence. The documented differences are practical: setting, session length and time required.

How much is absorbed from a subcutaneous injection?

Published human pharmacokinetic data for injected NAD+ is very limited, and this page does not publish a figure that the literature does not support.

Do the oral NAD+ studies apply?

Not directly. Those trials studied nicotinamide riboside or nicotinamide mononucleotide taken orally, which is a different molecule by a different route.

Sources

Every study named on this page, so you can check what it actually was:

• Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257. https://doi.org/10.3389/fnagi.2019.00257
• Reyna K, Heinzen G, Patel N, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. https://doi.org/10.3389/fragi.2026.1652582
• University of Maryland Center of Excellence in Regulatory Science and Innovation, prepared for the FDA. Summary Report: Nicotinamide adenine dinucleotide. February 2021. View report
• FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. View source

Last reviewed 10 September 2026. This is a fast moving area with very little settled evidence. Check the sources directly if you are reading this later.

Related reading

• The FDA peptide compounding status tracker, kept current
• NAD+ therapy: the complete guide
• NAD+ dosage and what determines it
• NAD+ side effects
• NAD+ nasal spray
• NAD+ IV versus injection versus nasal spray
• Is NAD+ FDA approved?
• BPC-157
• Glutathione therapy: the complete guide
• Peptide reconstitution calculator

Longevity plans from PrescribedRX

PrescribedRX prescribes longevity treatments through clinicians licensed in your state:

• Glutathione Injection. Administered by injection after a provider consultation.
• Glutathione Nasal Spray. A nasal alternative.
• NAD+ Injections. On a schedule set by your provider.
• NAD+ Nasal Spray. A nasal alternative.
• Sermorelin Injections. By prescription after consultation.

Every plan and its current price is on the plans page and the pricing page.

These are compounded preparations. Compounded drugs are not reviewed or approved by the FDA for safety or effectiveness, and treatment outcomes are not guaranteed.

This article is for general information. It is not medical advice and it is not a recommendation for any particular treatment. Whether a treatment is appropriate for you is a decision for a licensed clinician who has reviewed your health history and current medications.